Recent Posts
Connect with:
Saturday / July 20.
HomemiequipmentMenicon Bloom: A New Myopia Control Management System

Menicon Bloom: A New Myopia Control Management System

The Menicon Bloom Myopia Control Management System is a holistic approach for myopia control management that has been developed by Menicon to help stem the growing incidence of myopia and its health consequences worldwide. The system features Menicon Bloom Night, the first CE-approved orthokeratology contact lens for myopia control management, which will be launched to the Australian market this year. This article describes the way the new technology works.

Myopia is the most common refractive error and the major cause of vision impairment worldwide.1,2 Globally, it is recognised as a significant public health concern associated with increased ocular-related morbidity and considerable healthcare costs.3-6 It affects approximately 30% of the world’s population and its prevalence has been forecast to affect about 50% of the world’s population by 2050.1 The prevalence of myopia in young adolescents has been increasing in recent decades to about 30% in industrialised societies of the West and epidemic levels of over 90% in some parts of Far East Asia.1,7-12


Menicon Bloom Night therapy involves the overnight wear of a specially designed orthokeratology contact lens, manufactured in hyper oxygen permeable Menicon Z material to ensure optimal corneal oxygenation for safe and comfortable lens wear.13-17 The treatment temporarily changes the shape of the cornea by flattening and steepening the central and mid-peripheral corneal curvatures, respectively. These corneal changes occur overnight and reduce refractive error, thus eliminating the need to wear contact lenses throughout the waking hours after lenses are removed.18 The new corneal shape also provides a particular optical path for incoming light that counters the ocular growth response associated with myopia development.19

Menicon Bloom Night is indicated for the correction of refractive myopia and for the control of myopia when prescribed and managed by a qualified optometrist.

The myopia control therapy is currently available in two different contact lens designs: Menicon Bloom Night and Menicon Bloom Night Toric. Both lens types can correct up to -4.00D of myopia, with Menicon Bloom Night Toric providing additional options for correcting higher levels of corneal and refractive astigmatism.


Menicon Bloom Night contact lenses have been reviewed and validated via numerous comprehensive, peer-reviewed studies related to myopia control management. These studies provide conclusive support for the safety and efficacy of this treatment for myopia control management.18, 20-31


Like any other treatment, Menicon Bloom Night can be associated with the development of adverse events and complications. However, recent large studies, including meta-analyses and systematic reviews, have demonstrated that Menicon Bloom Night contact lenses, if fitted correctly by an optometrist according to the manufacturer’s instructions, are safe to use in younger populations.32-35 Specific studies performed with Menicon Bloom Night for myopia control management have shown that the complications associated with the use of the device are typically not considered to be serious; are similar to those reported with other contact lens types; and can be managed straightforwardly in clinical practice.22-25 Additionally, post-marketing surveillance and complaint trend data from the manufacturer, as well as potential adverse events reported with Menicon Bloom Night orthokeratology contact lenses in external databases, have been reviewed. Analysis of all this data has provided conclusive evidence supporting Menicon Bloom Night as a safe, viable myopia control treatment option.36 


Several peer-reviewed studies specifically conducted with Menicon Bloom Night for myopia control treatment have demonstrated significant levels of efficacy.22,23, 25 Furthermore, recent results demonstrate the successful long-term efficacy of Menicon Bloom Night in reducing myopia progression in children.18 All together, these studies have provided consistent evidence supporting the efficacy of the treatment for myopia control management.

With the accumulation of long-term and comprehensive scientific evidence over the years, Menicon Bloom Night has met the highest standards of safety, efficacy and quality required to grant the treatment CE approval for myopia control management in Europe. Menicon Bloom Night, if used correctly in accordance with the instructions for use, provides excellent benefits with very limited risks.


Menicon Bloom Night therapy has shown to be well-accepted by parents and to significantly improve vision-related quality of life in comparison to children wearing spectacles, thus providing an incentive to engage in its use for the control of myopia in children.27


The fitting of Menicon Bloom Night is optimised by the use of a corneal topographer to precisely measure corneal shape, in conjunction with Easyfit software, a sophisticated, user-friendly tool which accurately guides the optometrist through the fitting process. Additionally, a specially designed mobile phone application, the Bloom App, has been developed to enhance the monitoring and communication process between optometrists and patients. Menicon Bloom Night is only available for certified optometrists.


Marketing a medical device in Europe requires a marketing authorisation (‘product license’) for specified indications under specified conditions (e.g., target population, indication, specific use), regulated by the European Medical Agency.37,38 This process is employed to ensure that medical products meet the highest standards of safety, efficacy and quality before being issued a marketing authorisation. In Europe, products that hold a marketing authorisation are designated a ‘CE’ marking.

Prescribing a licensed product outside the approved scope of use is called ‘off-label’ prescribing. An example of off-label prescribing occurs when an orthokeratology contact lens, which is approved for the correction of manifest myopia in adults, is prescribed for reducing myopia progression in children, where both the indication (i.e. correcting manifest myopia vs. reducing myopia progression) and target group (i.e. adults vs. children) are different from those for which the product has been approved for.

When prescribing a treatment for myopia control, the optometrist should ideally start by considering all on-label products that may be available and only contemplate off-label prescribing if there are no on-label options, or if approved products are not effective or appropriate.41 In off-label prescribing, the patient must be adequately informed about the lack of product authorisation and the possible existence of unknown risks.40-44 Parents and legal guardians should be informed of all options and associated risks in order to decide whether the child should be treated with a tested and approved on-label treatment, or with an off-label treatment that might give a successful result, but has unknown risks.

With the official marketing authorisation for myopia control management, Menicon Bloom Night has met the highest standards of safety, efficacy and quality required to grant the treatment CE-approval for myopia control management in Europe. With such approval, optometrists can now have peace of mind with the on-label prescription of this myopia control therapy.

*Bloom, Bloom Night, Menicon Z and Easyfit are trademarks of Menicon Co., Ltd. menicon.com.au. 


  1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.
  2. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-e34.
  3. Vitale S, Cotch MF, Sperduto R, Ellwein L. Costs of refractive correction of distance vision impairment in the United States, 1999-2002. Ophthalmology. 2006;113(12):2163-70.
  4. Lim MC, Gazzard G, Sim EL, Tong L, Saw SM. Direct costs of myopia in Singapore. Eye (Lond). 2009;23(5):1086-9.
  5. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-60.
  6. Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, et al. IMI – Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20-M30.
  7. Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: a meta-analysis. Optom Vis Sci. 2015;92(3):258-66.
  8. Koh V, Yang A, Saw SM, Chan YH, Lin ST, Tan MM, et al. Differences in prevalence of refractive errors in young Asian males in Singapore between 1996-1997 and 2009-2010. Ophthalmic Epidemiol. 2014;21(4):247-55.
  9. Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt. 2012;32(1):3-16.
  10. Wang TJ, Chiang TH, Wang TH, Lin LL, Shih YF. Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005. Eye (Lond). 2009;23(5):1168-9.
  11. Vitale S, Sperduto RD, Ferris FL, 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009;127(12):1632-9.
  12. Gilmartin B. Myopia: precedents for research in the twenty-first century. Clin Exp Ophthalmol. 2004;32(3):305-24.
  13. Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697-708.
  14. Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, et al. IMI – Interventions myopia institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci. 2019;60(3):M106-M31.
  15. Si JK, Tang K, Bi HS, Guo DD, Guo JG, Wang XR. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci. 2015;92(3):252-7.
  16. Wen D, Huang J, Chen H, Bao F, Savini G, Calossi A, et al. Efficacy and acceptability of orthokeratology for slowing myopic progression in children: a systematic review and meta-Analysis. J Ophthalmol. 2015;2015:360806.
  17. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53(7):3913-9.
  18. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R, Sugimoto K. Long-term efficacy of orthokeratology contact lens wear in controlling the progression of childhood myopia. Curr Eye Res. 2017;42(5):713-20.
  19. Smith 3rd EL. Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone. Exp Eye Res 2013;114:77-88.
  20. Chan KY, Cheung SW, Cho P. Clinical performance of an orthokeratology lens fitted with the aid of a computer software in Chinese children. Cont Lens Anterior Eye. 2012;35(4):180-4.
  21. Chen CC, Cheung SW, Cho P. Toric orthokeratology for highly astigmatic children. Optom Vis Sci. 2012;89(6):849-55.
  22. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53(11):7077-85.
  23. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci. 2012;53(8):5060-5.
  24. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Orthokeratology vs. spectacles: adverse events and discontinuations. Optom Vis Sci. 2012;89(8):1133-9.
  25. Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci. 2013;54(10):6510-7.
  26. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Factors preventing myopia progression with orthokeratology correction. Optom Vis Sci. 2013;90(11):1225-36.
  27. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: a comparison of vision-related quality-of-life measures between orthokeratology contact lenses and single-vision spectacles. Eye Contact Lens. 2013;39(2):153-7.
  28. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Short-term changes in ocular biometry and refraction after discontinuation of long-term orthokeratology. Eye Contact Lens. 2014;40(2):84-90.
  29. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R, Suzaki A. The effects of entrance pupil centration and coma aberrations on myopic progression following orthokeratology. Clin Exp Optom. 2015;98(6):534-40.
  30. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R. Short-term and long-term changes in corneal power are not correlated with axial elongation of the eye induced by orthokeratology in children. Eye Contact Lens. 2016.
  31. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutierrez-Ortega R, Suzaki A. Short- and long-term changes in corneal aberrations and axial length induced by orthokeratology in children are not correlated. Eye Contact Lens. 2017;43(6):358-63.
  32. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci. 2013;90(9):937-44.
  33. Li SM, Kang MT, Wu SS, Liu LR, Li H, Chen Z, et al. Efficacy, safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Curr Eye Res. 2016;41(5):600-8.
  34. Liu YM, Xie P. The safety of orthokeratology–a systematic review. Eye Contact Lens. 2016;42(1):35-42.
  35. Bullimore MA, Mirsayafov DS, Khurai AR, Kononov LB, Asatrian SP, Shmakov AN, Richdale K, Gorev VV. Pediatric Microbial Keratitis With Overnight Orthokeratology in Russia. Eye Contact Lens 2021;47(7):420-425
  36. File MDo. Clinical evaluation report for menicon Z night orthokeratology contact lenses. 2017 26-07-2017. Contract No.: QA076-3.
  37. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90.
  38. Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017.
  39. Jones L, Drobe B, Gonzalez-Meijome JM, Gray L, Kratzer T, Newman S, et al. IMI – Industry guidelines and ethical considerations for myopia control report. Invest Ophthalmol Vis Sci. 2019;60(3):M161-M83.
  40. Riley JB, Jr., Basilius PA. Physicians’ liability for off-label prescriptions. Nephrol News Issues. 2007;21(7):43-4, 6-7.
  41. Wilkes M, Johns M. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. PLoS Med. 2008;5(11):e223.
  42. Lenk C, Koch P, Zappel H, Wiesemann C. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr. 2009;168(12):1473-8.
  43. Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag. 2014;10:537-46.
  44. Weda M, Hoebert, J., Vervloet, M., Moltó Puigmarti, C., Damen, N., Marchange, S., Langedijk, J., Lisman, J., van Dijk, L. Study on off-label use of medicinal products in the European Union. 2017.